INCY News and Press, Incyte Corporation From 08/03/21

Image source: The Motley Fool. Incyte Corporation (NASDAQ: INCY) Q2 2021 Earnings Call Aug 3, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Incyte Corporation (INCY) Q2 2021 Earnings Call Transcript

Incyte Corporation (INCY) Q2 2021 Earnings Conference Call August 03, 2021, 08:00 AM ET Company Participants Christine Chiou - Senior Director, Investor Relations Hervé Hoppenot - Chairman, President and Chief Executive Officer Barry Flannelly - Executive Vice President and General Manag...

The following slide deck was published by Incyte Corporation in conjunction with their 2021 Q2 earnings call. For further details see: Incyte Corporation 2021 Q2 - Results - Earnings Call Presentation

Incyte (NASDAQ:INCY) reports Q2 2021 results and provides an update on its development portfolio. Total revenues rose marginally by 2.6% to $705.7M, surpassing analyst estimates of $686.95M. Jakafi and Iclusig net product revenues rose 12% and 24%, respectively to $529.1M and $28.2M. Pemazyre...

Incyte (NASDAQ:INCY): Q2 Non-GAAP EPS of $0.80 beats by $0.06; GAAP EPS of $0.67 beats by $0.12. Revenue of $705.71M (+2.6% Y/Y) beats by $18.76M. Jakafi (ruxolitinib) revenues of $529M in Q2 2021 (+12% vs Q2 2020) FY21 Outlook: Jakafi (ruxolitinib) revenues of $2,125M - $2,170M from pri...

- Total product and royalty revenues of $696 million in Q2 2021 (+17% vs Q2 2020) - Jakafi ® (ruxolitinib) revenues of $529 million in Q2 2021 (+12% vs Q2 2020) - Positive CHMP opinion for tafasitamab in combination with lenalidomide for the treatment of a...

Eli Lilly (NYSE:LLY) and Incyte (NASDAQ:INCY) announce results from an additional cohort of 101 adult patients from the COV-BARRIER trial. In this sub-study, patients with COVID-19 on mechanical ventilation or extracorporeal membrane oxygenation (ECMO) who received baricitinib plus standard o...

Lilly and Incyte's baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation - New data from Phase 3 COV-BARRIER sub-study indicates one death prevented for every six baricitinib-treated patients on mechanical ventilation or ECMO compared ...

Calithera is guiding for the market to expect what we believe will be a key data read-out from its ongoing CB-280 study involving Cystic Fibrosis. We anticipate full data set to read out in early October at the North American Cystic Fibrosis Conference. A positive read-out here co...

Using the quarterly 13F filings, we extract 50 consensus stocks from 40 large hedge funds, each fund with more than $3.5 billion Assets Under Management. After the Q1-2021 13F filings, the consensus holdings are updated, 5 stocks were removed and 6 added from the universe; now holds 4...